Cover Image
市場調查報告書

腎性貧血:開發平台分析

Renal Anemia - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 192801
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
腎性貧血:開發平台分析 Renal Anemia - Pipeline Review, H2 2015
出版日期: 2015年10月30日 內容資訊: 英文 124 Pages
簡介

腎臟可分泌促進紅血球運作的促血紅細胞生長素這個蛋白質,這個促血紅細胞生長素不足便會造成貧血。可以看到皮膚泛青、牙齦泛青等症狀,再加上呼吸急促和暈眩,以及無法明確思考。

本報告提供腎性貧血的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

腎性貧血概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • Acceleron Pharma, Inc.
  • Akebia Therapeutics, Inc.
  • Amgen Inc.
  • Aprogen, Inc.
  • Bayer AG
  • BIOCAD
  • CCM Duopharma Biotech Bhd.
  • Chong Kun Dang Pharmaceutical Corp.
  • 第一三共
  • Dong-A Socio Group
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • FibroGen, Inc.
  • GlaxoSmithKline Plc
  • Intas Pharmaceuticals Ltd.
  • 日本煙草產業
  • JCR Pharmaceuticals Co., Ltd.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Medgenics Inc.
  • Myungmoon pharmaceutical Co., Ltd.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • ProMetic Life Sciences Inc.
  • Sandoz International GmbH
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Biologic for Renal Anemia
  • daprodustat
  • darbepoetin alfa
  • darbepoetin alfa
  • darbepoetin alfa
  • darbepoetin alfa
  • darbepoetin alfa
  • darbepoetin alfa
  • darbepoetin alfa
  • darbepoetin alfa (recombinant)
  • DS-1093
  • EPO-018B
  • epoetin
  • epoetin alfa
  • epoetin alfa (recombinant)
  • FG-2216
  • JTZ-951
  • MDGN-201
  • MMP-0101
  • molidustat
  • PBI-1402
  • PEG-EPO
  • Peg-EPO
  • PEG-EPO
  • PRS-080
  • Recombinant Protein for Renal Anemia
  • roxadustat
  • Small Molecule to Inhibit HIF-PH for Renal Anemia
  • sotatercept
  • SSS-06
  • vadadustat

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7230IDB

Summary

Global Markets Direct's, 'Renal Anemia - Pipeline Review, H2 2015', provides an overview of the Renal Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Renal Anemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Renal Anemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Renal Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Renal Anemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Renal Anemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Renal Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Renal Anemia Overview
  • Therapeutics Development
    • Pipeline Products for Renal Anemia - Overview
  • Renal Anemia - Therapeutics under Development by Companies
  • Renal Anemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Renal Anemia - Products under Development by Companies
  • Renal Anemia - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Akebia Therapeutics, Inc.
    • Amgen Inc.
    • Aprogen, Inc.
    • Bayer AG
    • BIOCAD
    • CCM Duopharma Biotech Bhd.
    • Chong Kun Dang Pharmaceutical Corp.
    • Daiichi Sankyo Company, Limited
    • Dong-A Socio Group
    • Dr. Reddy's Laboratories Limited
    • Eli Lilly and Company
    • FibroGen, Inc.
    • GlaxoSmithKline Plc
    • Intas Pharmaceuticals Ltd.
    • Japan Tobacco Inc.
    • JCR Pharmaceuticals Co., Ltd.
    • Jiangsu Hansoh Pharmaceutical Co., Ltd.
    • Medgenics Inc.
    • Myungmoon pharmaceutical Co., Ltd.
    • Panacea Biotec Limited
    • Pfizer Inc.
    • ProMetic Life Sciences Inc.
    • Sandoz International GmbH
    • Zydus Cadila Healthcare Limited
  • Renal Anemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Biologic for Renal Anemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • daprodustat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DS-1093 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EPO-018B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epoetin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epoetin alfa (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FG-2216 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JTZ-951 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MDGN-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MMP-0101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • molidustat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-1402 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-EPO - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peg-EPO - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-EPO - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRS-080 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Renal Anemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • roxadustat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit HIF-PH for Renal Anemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sotatercept - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SSS-06 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vadadustat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Renal Anemia - Recent Pipeline Updates
  • Renal Anemia - Dormant Projects
  • Renal Anemia - Discontinued Products
  • Renal Anemia - Product Development Milestones
    • Featured News & Press Releases
      • Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia
      • Jul 15, 2015: Medgenics Announces First Patient Enrolled in U.S.-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis
      • May 26, 2015: Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress
      • Mar 27, 2015: Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen
      • Mar 16, 2015: Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia at WCN
      • Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat
      • Mar 10, 2015: Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease
      • Oct 15, 2014: Medgenics Reports Positive Initial Clinical Data From Clinical Study Of MDGN-201
      • Sep 13, 2013: Approval of Additional Indication of Long-Acting Erythropoiesis-Stimulating Agent NESP for Pediatric Patients with renal anemia in Japan
      • Jul 31, 2013: Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Renal Anemia, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd...1)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd...1)
  • Products under Development by Companies, H2 2015 (Contd...2)
  • Renal Anemia - Pipeline by 3SBio Inc., H2 2015
  • Renal Anemia - Pipeline by Acceleron Pharma, Inc., H2 2015
  • Renal Anemia - Pipeline by Akebia Therapeutics, Inc., H2 2015
  • Renal Anemia - Pipeline by Amgen Inc., H2 2015
  • Renal Anemia - Pipeline by Aprogen, Inc., H2 2015
  • Renal Anemia - Pipeline by Bayer AG, H2 2015
  • Renal Anemia - Pipeline by BIOCAD, H2 2015
  • Renal Anemia - Pipeline by CCM Duopharma Biotech Bhd., H2 2015
  • Renal Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
  • Renal Anemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Renal Anemia - Pipeline by Dong-A Socio Group, H2 2015
  • Renal Anemia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
  • Renal Anemia - Pipeline by Eli Lilly and Company, H2 2015
  • Renal Anemia - Pipeline by FibroGen, Inc., H2 2015
  • Renal Anemia - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Renal Anemia - Pipeline by Intas Pharmaceuticals Ltd., H2 2015
  • Renal Anemia - Pipeline by Japan Tobacco Inc., H2 2015
  • Renal Anemia - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2015
  • Renal Anemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015
  • Renal Anemia - Pipeline by Medgenics Inc., H2 2015
  • Renal Anemia - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H2 2015
  • Renal Anemia - Pipeline by Panacea Biotec Limited, H2 2015
  • Renal Anemia - Pipeline by Pfizer Inc., H2 2015
  • Renal Anemia - Pipeline by ProMetic Life Sciences Inc., H2 2015
  • Renal Anemia - Pipeline by Sandoz International GmbH, H2 2015
  • Renal Anemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Renal Anemia Therapeutics - Recent Pipeline Updates, H2 2015
  • Renal Anemia - Dormant Projects, H2 2015
  • Renal Anemia - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Renal Anemia, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top